Publications by authors named "Rossana L Segura"
Article Synopsis
- Solitary fibrous tumor (SFT) is a rare type of tumor that can occur in various body parts and is often linked to specific genetic fusions, with 10-30% of cases becoming metastatic.
- A study involving DNA methylation analysis of 79 SFTs revealed distinct epigenetic changes linked to their primary sites, identifying key genes such as EGFR and TBX15 that showed differing levels of expression based on the tumor's location and genetic fusion type.
- TBX15 emerged as a significant marker, with changes in its methylation and expression strongly correlating to the tumor's tissue of origin, suggesting it could help differentiate between new tumors and metastases without needing extensive genomic analysis.
Multi-modal spatial omics data are invaluable for exploring complex cellular behaviors in diseases from both morphological and molecular perspectives. Current analytical methods primarily focus on clustering and classification, and do not adequately examine the relationship between cell morphology and molecular dynamics. Here, we present MorphLink, a framework designed to systematically identify disease-related morphological-molecular interplays.
View Article and Find Full Text PDFArticle Synopsis
- Despite the notable advancements in immunotherapy for cancer, only a small percentage (less than 20%) show lasting responses to immune checkpoint blockade, leading researchers to consider combination therapies that target multiple immune evasion strategies.
- Researchers analyzed data from over 1,000 tumors across ten cancers to identify seven distinct immune subtypes, examining their unique genomic, epigenetic, transcriptomic, and proteomic characteristics.
- By investigating kinase activities linked to these immune subtypes, the study uncovered potential therapeutic targets that could improve future immunotherapy approaches and precision medicine.
Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized care in melanoma and other cancers; however, therapeutic resistance is common and innovative treatment strategies are needed. Here we studied a group of patients with melanoma who were treated with neoadjuvant BRAF/MEK-targeted therapy ( NCT02231775 , n = 51) and observed significantly higher rates of major pathological response (MPR; ≤10% viable tumour at resection) and improved recurrence-free survival (RFS) in female versus male patients (MPR, 66% versus 14%, P = 0.001; RFS, 64% versus 32% at 2 years, P = 0.
View Article and Find Full Text PDF